Detailed Information

Cited 10 time in webofscience Cited 11 time in scopus
Metadata Downloads

Urinary tissue inhibitor of metalloproteinase-2 and insulin-like growth factor-binding protein 7 as biomarkers of patients with established acute kidney injuryopen access

Authors
Cho, Won YongLim, Sung YoonYang, Ji HyunOh, Se WonKim, Myung-GyuJo, Sang-Kyung
Issue Date
May-2020
Publisher
대한내과학회
Keywords
Acute kidney injury; Biomarker; Tissue inhibitor metalloproteinase-2; Insulin-like growth factor-binding protein 7
Citation
The Korean Journal of Internal Medicine, v.35, no.3, pp 662 - 671
Pages
10
Indexed
SCIE
SCOPUS
KCI
Journal Title
The Korean Journal of Internal Medicine
Volume
35
Number
3
Start Page
662
End Page
671
URI
https://scholarworks.korea.ac.kr/kumedicine/handle/2020.sw.kumedicine/838
DOI
10.3904/kjim.2018.266
ISSN
1226-3303
2005-6648
Abstract
Background/Aims Urinary tissue inhibitor of metalloproteinase-2 (TIMP-2) and insulin-like growth factor-binding protein 7 (IGFBP7) have been recently discovered and validated as sensitive biomarkers that can predict stage 2 or 3 acute kidney injury (AKI) development in high-risk patients. We aimed to assess whether these biomarkers could predict adverse outcomes and renal recovery in established AKI patients. Methods This was a single-center study prospectively enrolling 124 patients diagnosed with AKI. TIMP-2, IGFBP7, neutrophil gelatinase-associated lipocalin (NGAL), and kidney injury molecule 1 (KIM-1) levels were measured at the time of diagnosis and the predictive performance of short-term outcomes and renal recovery was assessed. Results Patients were divided into 4 quartiles according to the initial urinary TIMP-2/IGFBP7 levels. Stage 3 AKI (odds ratio [OR], 17.86), classified by the Kidney Disease Improving Global Outcomes (KDIGO), as well as the third and fourth quartiles of TIMP-2/IGFBP7 (OR, 5.75 and 44.98, respectively), were found to be independent predictors of renal replacement therapy at the time of AKI diagnosis. In addition, KDIGO stage 3 AKI (OR, 2.468) or the third of fourth quartiles of urinary TIMP-2/IGFBP7 (OR, 1.896 and 3.622, respectively) were also found to be useful in predicting nonrecovery of renal function. In a separate analysis of patients with renal recovery at discharge, initial urinary TIMP-2/IGFBP7 or urinary IGFBP7 at discharge could also predict new-onset or progressive chronic kidney disease (CKD). Conclusions In AKI patients, urine TIMP-2/IGFBP7 could serve as a biomarker for predicting adverse outcomes, renal recovery, or the development and progression of CKD.
Files in This Item
There are no files associated with this item.
Appears in
Collections
2. Clinical Science > Department of Nephrology and Hypertension > 1. Journal Articles

qrcode

Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.

Related Researcher

Researcher Jo, Sang Kyung photo

Jo, Sang Kyung
Anam Hospital (Department of Nephrology and Hypertension, Anam Hospital)
Read more

Altmetrics

Total Views & Downloads

BROWSE